Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says

MT Newswires Live

Oct 13, 2025

Mesoblast's (ASX:MSB) quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.

Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.

The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.

The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575276394"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575276394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575276394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 14:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575276394","market":"sg","top_or_hot":-1,"title":"Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> Mesoblast's (ASX:MSB) quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.</p><p>Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.</p><p>The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.</p><p>The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-13 14:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast's (ASX:MSB) quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.</p><p>Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.</p><p>The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.</p><p>The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575276394","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575276394","pubTimestamp":1760338274,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast's  quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MSB.AU":"MESOBLAST LTD","BK7067":"生物科技","BK7508":"医药生物股","BK7501":"新冠治疗股","MESO":"Mesoblast Limited"},"translate_title":"Jefferies表示，Mesoblast将于2026财年完成对63名患者的Ryoncil治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1,"MESO":1.5},"content_text":"Mesoblast's (ASX:MSB) quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}